Jacc: Cardiooncology最新文献

{"title":"Biomarkers to Predict Abnormal Technetium-99m Pyrophosphate Scans in Patients With Suspected Transthyretin Amyloidosis","authors":"Laura De Michieli MD ,&nbsp;Omar F. AbouEzzeddine MDCM, MS ,&nbsp;Muhannad A. Abbasi MD ,&nbsp;Daniel R. Davies MD ,&nbsp;Christopher G. Scott MS ,&nbsp;Eli Muchtar MD ,&nbsp;Angela Dispenzieri MD ,&nbsp;Martha Grogan MD ,&nbsp;Margaret M. Redfield MD ,&nbsp;Allan S. Jaffe MD","doi":"10.1016/j.jaccao.2024.10.013","DOIUrl":"10.1016/j.jaccao.2024.10.013","url":null,"abstract":"<div><h3>Background</h3><div>Technetium Tc 99m pyrophosphate scintigraphy (^99mTc PYP imaging) is a diagnostic tool for transthyretin amyloid cardiomyopathy (ATTR-CM). Cardiac biomarkers, particularly high-sensitivity cardiac troponin (hs-cTn) and N-terminal pro–B-type natriuretic peptide (NT-proBNP), may help identify patients at low or high risk for ATTR-CM.</div></div><div><h3>Objectives</h3><div>The authors sought to evaluate the predictive value of hs-cTnT and NT-proBNP in patients undergoing ^99mTc PYP imaging for suspected ATTR-CM in a large U.S. cohort.</div></div><div><h3>Methods</h3><div>This was a retrospective study of patients who underwent ^99mTc PYP imaging between May 2013 and September 2022, including those with at least 1 hs-cTnT measurement within 6 months of the scan.</div></div><div><h3>Results</h3><div>ATTR-CM was diagnosed in 427 of 1,442 patients (29.6%). A hs-cTnT level &lt;6 ng/L (n = 50, 3.5%) showed a negative predictive value of 100% (95% CI: 93%-100%) and sensitivity of 100% (95% CI: 99%-100%) for ruling out ATTR-CM. As the hs-cTnT threshold increased, the number of patients who could be ruled out also increased, but false negatives emerged. The positive predictive value for ruling in ATTR-CM remained low. NT-proBNP showed similar results (n = 1,378). The combination of hs-cTnT &lt;14 ng/L and NT-proBNP &lt;60 ng/L identified 45 patients (3.3%) without ATTR-CM.</div></div><div><h3>Conclusions</h3><div>In patients undergoing ^99mTc PYP imaging for suspected ATTR-CM, very low hs-cTnT levels can effectively rule out the diagnosis, although in a small subset of patients. Higher thresholds increase the risk of false negatives. NT-proBNP and combined biomarker strategies showed similar trends, the utility of hs-cTnT and NT-proBNP for ruling in the disease is limited.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 1","pages":"Pages 70-78"},"PeriodicalIF":12.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11781999/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum Proteins Predict Treatment-Related Cardiomyopathy Among Survivors of Childhood Cancer","authors":"Suresh Poudel PhD ,&nbsp;Him Shrestha PhD ,&nbsp;Yue Pan PhD ,&nbsp;Qian Li PhD ,&nbsp;Kendrick Li PhD ,&nbsp;Cindy Im PhD ,&nbsp;Stephanie B. Dixon MD ,&nbsp;Matthew J. Ehrhardt MD ,&nbsp;Daniel A. Mulrooney MD ,&nbsp;Suiping Zhou PhD ,&nbsp;Haiyan Tan PhD ,&nbsp;Anthony A. High PhD ,&nbsp;Paul W. Burridge PhD ,&nbsp;Smita Bhatia MD ,&nbsp;John L. Jefferies MD ,&nbsp;Kirsten K. Ness PhD ,&nbsp;Melissa M. Hudson MD ,&nbsp;Leslie L. Robison PhD ,&nbsp;Gregory T. Armstrong MD ,&nbsp;Junmin Peng PhD ,&nbsp;Yadav Sapkota PhD","doi":"10.1016/j.jaccao.2024.10.004","DOIUrl":"10.1016/j.jaccao.2024.10.004","url":null,"abstract":"<div><h3>Background</h3><div>Anthracyclines, a highly effective chemotherapy for many pediatric malignancies, cause cardiomyopathy, a major late effect in adult survivors. Biomarkers are needed for early detection and targeted interventions for anthracycline-associated cardiomyopathy.</div></div><div><h3>Objectives</h3><div>The aim of this study was to determine if serum proteins and/or metabolites in asymptomatic childhood cancer survivors can discriminate symptomatic cardiomyopathy.</div></div><div><h3>Methods</h3><div>Using an untargeted mass spectrometry–based approach, 867 proteins and 218 metabolites were profiled in serum samples of 75 asymptomatic survivors with subclinical cardiomyopathy and 75 individually matched survivors without cardiomyopathy from SJLIFE (St. Jude Lifetime Cohort Study). Models were developed on the basis of the most influential differentially expressed proteins and metabolites, using conditional logistic regression with a least absolute shrinkage and selection operator penalty. The best performing model was evaluated in 23 independent survivors with severe or symptomatic cardiomyopathy and 23 individually matched cardiomyopathy-free survivors.</div></div><div><h3>Results</h3><div>A 27-protein model identified using conditional logistic regression with a least absolute shrinkage and selection operator penalty discriminated symptomatic or severe cardiomyopathy requiring heart failure medications in independent survivors; 19 of 23 individually matched survivors with and without cardiomyopathy were correctly discriminated with 82.6% (95% CI: 71.4%-93.8%) accuracy. Pathway enrichment analysis revealed that the 27 proteins were enriched in various biological processes, many of which have been linked to anthracycline-related cardiomyopathy.</div></div><div><h3>Conclusions</h3><div>A risk model was developed on the basis of the differential expression of serum proteins in subclinical cardiomyopathy, which accurately discriminated the risk for severe cardiomyopathy in an independent, matched sample. Further assessment of these proteins as biomarkers of cardiomyopathy risk should be conducted in external larger cohorts and through prospective studies.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 1","pages":"Pages 56-67"},"PeriodicalIF":12.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11782007/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heart Failure Post-Hematopoietic Cell Transplantation in Patients With Lymphoma","authors":"Oscar Calvillo-Argüelles MD ,&nbsp;Robert J. Vanner MD, PhD","doi":"10.1016/j.jaccao.2024.12.001","DOIUrl":"10.1016/j.jaccao.2024.12.001","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 1","pages":"Pages 34-37"},"PeriodicalIF":12.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11782005/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143080777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing Life’s Essential 8 for Cardiovascular Risk Assessment in Breast Cancer Survivors","authors":"Shanshan Gao MD,&nbsp;Jingjjing Mu MD,&nbsp;Beina Hui MD,&nbsp;Weibin Hu MD,&nbsp;Yongkai Lu PhD","doi":"10.1016/j.jaccao.2024.09.010","DOIUrl":"10.1016/j.jaccao.2024.09.010","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 6","pages":"Page 987"},"PeriodicalIF":12.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711818/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lutetium-177 DOTATATE Therapy and Cardiac Outcomes in Patients With Neuroendocrine Tumor and Cardiac Metastases","authors":"Isabel G. Scalia MD ,&nbsp;Mohamad Bassam Sonbol MD ,&nbsp;Juan M. Farina MD ,&nbsp;Milagros Pereyra MD ,&nbsp;Yuxiang Wang MD ,&nbsp;Tanios S. Bekaii-Saab MD ,&nbsp;Ming Yang MD ,&nbsp;Heidi M. Connolly MD ,&nbsp;Patricia A. Pellikka MD ,&nbsp;Joerg Herrmann MD ,&nbsp;Thorvardur R. Halfdanarson MD ,&nbsp;Jason S. Starr DO ,&nbsp;Sushil Allen Luis MBBS, PhD ,&nbsp;Reza Arsanjani MD ,&nbsp;Chadi Ayoub MBBS, PhD","doi":"10.1016/j.jaccao.2024.09.008","DOIUrl":"10.1016/j.jaccao.2024.09.008","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 6","pages":"Pages 982-984"},"PeriodicalIF":12.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11712006/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atherosclerotic Cardiovascular Diseases Are Associated With Incident Metastatic and Nonmetastatic Cancer","authors":"Tal Caller MSc ,&nbsp;Alexander Fardman MD ,&nbsp;Yariv Gerber PhD ,&nbsp;Yonatan Moshkovits BSc ,&nbsp;Shmuel Tiosano MD ,&nbsp;Alon Kaplan BSc ,&nbsp;Maia Kalstein BSc ,&nbsp;Gabriella Bayshtok BSc ,&nbsp;Tomer Itkin PhD ,&nbsp;Abraham Avigdor MD ,&nbsp;Nili Naftali-Shani PhD ,&nbsp;Jonathan Leor MD ,&nbsp;Elad Maor MD, PhD","doi":"10.1016/j.jaccao.2024.07.020","DOIUrl":"10.1016/j.jaccao.2024.07.020","url":null,"abstract":"<div><h3>Background</h3><div>Cardiovascular diseases are associated with higher cancer risk. However, their relationship with metastatic cancer, the primary determinant of cancer prognosis, has not been studied.</div></div><div><h3>Objectives</h3><div>This study aimed to determine the association between atherosclerotic cardiovascular disease and the presence of metastasis at the time of cancer diagnosis.</div></div><div><h3>Methods</h3><div>We analyzed data from 21,654 self-referred adults who were free of cancer and atherosclerotic cardiovascular disease at enrollment in a preventive health care program. To exclude silent cancers, a 1-year blanking period was implemented at the start of the follow-up. The relationship between atherosclerotic cardiovascular disease and metastatic cancer was assessed using cause-specific Cox regression, treating incident atherosclerotic cardiovascular disease as a time-dependent covariate. Interaction analysis further elucidated differences in metastasis risks between middle-aged adults (Q1-Q3 age ≤54 years) and older adults (Q4 age &gt;54 years).</div></div><div><h3>Results</h3><div>Over a median follow-up of 6 years (Q1-Q3: 3-12 years), we recorded 1,333 cases of atherosclerotic cardiovascular disease (6.2%) and 1,793 cases of cancer (8.3%), of which 1,036 (4.8 %) were nonmetastatic and 757 (3.5%) were metastatic at diagnosis. After adjusting for shared risk factors, atherosclerotic cardiovascular disease was independently associated with an increased risk of cancer metastasis at the time of cancer diagnosis (HR: 1.75; 95% CI: 1.33-2.29). This association was more pronounced among middle-aged adults (HR: 1.64; 95% CI: 1.03-2.61; <em>P</em> = 0.036) than in older adults (HR: 1.11; 95% CI: 0.78-1.60; <em>P</em> = 0.56), with a significant interaction (<em>P</em>_interaction = 0.039).</div></div><div><h3>Conclusions</h3><div>Atherosclerotic cardiovascular disease is associated with a significantly increased risk of cancer, specifically metastasis at the time of cancer diagnosis, particularly in middle-aged adults. Recognizing this association could enhance the prevention and treatment of metastatic cancer in patients with atherosclerotic cardiovascular disease.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 6","pages":"Pages 949-961"},"PeriodicalIF":12.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711827/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer Prevention and Early Detection in Patients With Cardiovascular Disease","authors":"Pietro Ameri MD, PhD ,&nbsp;Susan Dent MD","doi":"10.1016/j.jaccao.2024.09.009","DOIUrl":"10.1016/j.jaccao.2024.09.009","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 6","pages":"Pages 962-964"},"PeriodicalIF":12.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711806/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Net Clinical Benefit of 12-Month Over 3-Month Edoxaban in Cancer-Associated Isolated Distal Deep Vein Thrombosis","authors":"Yuji Nishimoto MD ,&nbsp;Yugo Yamashita MD ,&nbsp;Takeshi Morimoto MD, MPH ,&nbsp;Nao Muraoka MD ,&nbsp;Michihisa Umetsu MD ,&nbsp;Takuma Takada MD ,&nbsp;Yoshito Ogihara MD ,&nbsp;Tatsuya Nishikawa MD ,&nbsp;Nobutaka Ikeda MD ,&nbsp;Yukihito Sato MD ,&nbsp;Takahisa Yamada MD ,&nbsp;Takeshi Kimura MD ,&nbsp;ONCO DVT Study Investigators","doi":"10.1016/j.jaccao.2024.07.019","DOIUrl":"10.1016/j.jaccao.2024.07.019","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 6","pages":"Pages 979-981"},"PeriodicalIF":12.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711822/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SGLT2 Inhibitors in Mitigating Cancer Therapy-Related Cardiac Dysfunction","authors":"Mohamed S. Dabour MS ,&nbsp;Anne H. Blaes MD, MS ,&nbsp;Bhavadharini Ramu MD ,&nbsp;Beshay N. Zordoky MS, PhD","doi":"10.1016/j.jaccao.2024.10.005","DOIUrl":"10.1016/j.jaccao.2024.10.005","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 6","pages":"Pages 876-878"},"PeriodicalIF":12.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711823/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer Diagnosis, Physical Activity, and Heart Disease Risk","authors":"Emmanuel Stamatakis PhD ,&nbsp;Nicholas A. Koemel PhD ,&nbsp;Raaj K. Biswas PhD ,&nbsp;Matthew N. Ahmadi PhD","doi":"10.1016/j.jaccao.2024.11.002","DOIUrl":"10.1016/j.jaccao.2024.11.002","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 6","pages":"Pages 890-892"},"PeriodicalIF":12.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11712014/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}